Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis

Bakouny Z., Yekeduz E., Braun D. A., Berchuck J. E., Hirsch L., UTKAN G., ...Daha Fazla

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, cilt.166, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 166
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.critrevonc.2021.103463
  • Dergi Adı: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Anahtar Kelimeler: Adverse events, Meta-analysis, Neurologic, Prostate cancer, Toxicities, ENZALUTAMIDE, BICALUTAMIDE, SURVIVAL, EFFICACY, SAFETY
  • Ankara Üniversitesi Adresli: Evet

Özet

Introduction: Novel non-steroidal anti-androgens (NSAA) are increasingly part of the management of prostate cancer. We aimed to quantify and compare the neurologic side effects of NSAA agents. Materials and methods: Phase III randomized controlled trials evaluating NSAAs in the treatment of prostate cancer were selected by two reviewers independently in MEDLINE. A random-effects model and the MantelHaenszel method were used. The Odds Ratio (OR) and its 95 % confidence interval were computed. The primary endpoints were the rates of neurologic adverse events. Results: Eight phase III trials evaluating novel NSAAs (vs. non-NSAAs) were included. Fatigue (OR:1.66 [1.32-2.08]), falls (OR:1.76 [1.25-2.49]), headache (OR:1.74 [1.42-2.14]), and dizziness (OR:1.70 [1.33-2.19]) were found to be significantly associated with NSAA use. Conclusions: NSAAs are associated with an increase in various neurologic adverse events. When NSAAs are prescribed, neurologic adverse event prevention and management strategies should be discussed and implemented.